Faraday Pharmaceuticals to Participate in Upcoming Investor Events

Topline data from pivotal Phase 3 Iocyte AMI-3 trial expected in Q4 2025

SEATTLE, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on preventing heart failure by reducing myocardial damage in acute ST-elevation myocardial infarction (STEMI) through the reduction of ischemia-reperfusion injury, today announced that management will be participating in the following upcoming virtual investor events:

Oppenheimer’s Private Life Sciences Company Showcase

Cantor Private Biotech Company Series

5^th Annual Needham Private Biotech and MedTech Company Forum

Please contact your institutional representative to request a one-on-one meeting with management. To attend the Cantor fireside chat webinar, please contact your research representative for a registration link.

About Faraday Pharmaceuticals, Inc.
Faraday Pharmaceuticals^® is a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage in acute STEMI. The company was founded by Dr. Mark Roth of the Fred Hutch Cancer Center and is backed by an investor group led by ARCH Venture Partners and Polaris Partners. The company is headquartered in Seattle. For more information, visit www.faradaypharma.com or follow the company on LinkedIn.

Contact:
Brian Blackman
Chief Financial Officer
bblackman@faradaypharma.com

PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.